• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Gram-Positive Bacterial Infections - Pipeline Review, H2 2012 Product Image

Gram-Positive Bacterial Infections - Pipeline Review, H2 2012

  • Published: October 2012
  • 342 pages
  • Global Markets Direct

Gram-Positive Bacterial Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Gram-Positive Bacterial Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gram-Positive Bacterial Infections.
- READ MORE >

2
List of Tables 18
List of Figures 20
Introduction 21
REPORT COVERAGE 21
Gram-Positive Bacterial Infections Overview 22
Therapeutics Development 23
An Overview of Pipeline Products for Gram-Positive Bacterial Infections 23
Gram-Positive Bacterial Infections Therapeutics under Development by Companies 25
Gram-Positive Bacterial Infections Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
Gram-Positive Bacterial Infections Therapeutics – Products under Development by Companies 38
Gram-Positive Bacterial Infections Therapeutics – Products under Investigation by Universities/Institutes 47
Companies Involved in Gram-Positive Bacterial Infections Therapeutics Development 48
Sequella, Inc. 48
AstraZeneca PLC 49
GlaxoSmithKline plc 50
Genentech, Inc. 51
Merck & Co., Inc. 52
Emergent BioSolutions Inc. 53
ACE BioSciences A/S 54
Nanotherapeutics, Inc. 55
Rib-X Pharmaceuticals, Inc. 56
Nabi Biopharmaceuticals 57
Actelion Ltd 58
BioMarin Pharmaceutical Inc. 59
Cubist Pharmaceuticals, Inc. 60
Forest Laboratories, Inc. 61
Pfizer Inc. 62
ViroPharma Incorporated 63
Wockhardt Limited 64
Hadasit Medical Research Services & Development Ltd 65
Optimer Pharmaceuticals, Inc. 66
Paratek Pharmaceuticals, Inc. 67
XTL Biopharmaceuticals Ltd. 68
Affinium Pharmaceuticals, Inc. 69
Immtech Pharmaceuticals, Inc. 70
Intercell AG 71
Basilea Pharmaceutica Ltd. 72
Biota Holdings Limited 73
Nymox Pharmaceutical Corporation 74
Oragenics, Inc. 75
Patrys Limited 76
CytoGenix, Inc. 77
ADVENTRX Pharmaceuticals 78
SIGA Technologies, Inc. 79
XOMA Ltd. 80
Immuron Limited 81
Dongwha Pharm Co., Ltd. 82
Theravance, Inc. 83
Panacea Biotec Limited 84
Summit Corporation plc 85
Phynova Group Ltd 86
Eurocine Vaccines AB 87
PolyMedix, Inc. 88
e-Therapeutics plc 89
Morphotek, Inc. 90
ActogeniX NV 91
Bharat Biotech International Limited 92
Mucosis B.V. 93
Evolva SA 94
Novacta Biosystems Limited 95
GlycoVaxyn AG 96
ConjuGon, Inc. 97
PLANTON GmbH 98
ImmunoBiology Limited 99
Aquapharm Biodiscovery Limited 100
Osel Inc. 101
AiCuris GmbH & Co. KG 102
Destiny Pharma Ltd. 103
NovaDigm Therapeutics, Inc. 104
Ferrer Internacional S.A. 105
Kenta Biotech Ltd. 106
aRigen Pharmaceuticals, Inc. 107
Sinovac Biotech Ltd. 108
Viral Genetics, Inc. 109
Microbiotix, Inc. 110
Integrated BioTherapeutics, Inc. 111
KYORIN Pharmaceutical Co., Ltd. 112
Trius Therapeutics, Inc. 113
Genocea Biosciences, Inc. 114
Biosynexus Incorporated 115
Lytix Biopharma AS 116
Phico Therapeutics Ltd. 117
NasVax Ltd. 118
Sorrento Therapeutics, Inc. 119
PepTx, Inc. 120
Morphochem AG 121
Cantab Biopharmaceuticals Limited 122
Gram-Positive Bacterial Infections – Therapeutics Assessment 123
Assessment by Monotherapy Products 123
Assessment by Combination Products 124
Assessment by Route of Administration 125
Assessment by Molecule Type 127
Drug Profiles 130
surotomycin - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
AFN-1252 - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
lysostaphin - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Antibiotic Program - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Sortase Inhibitor - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 154
MU-1140 - Drug Profile 155
Product Description 155
Mechanism of Action 155
R&D Progress 155
NXB-5886 - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
NXT-1021 - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
oritavancin disphosphate - Drug Profile 173
Product Description 173
Mechanism of Action 173
R&D Progress 173
SQ-641 - Drug Profile 175
Product Description 175
Mechanism of Action 175
R&D Progress 175
ACE-820 - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
ACE-720 - Drug Profile 177
Product Description 177
Mechanism of Action 177
R&D Progress 177
ETX1153c - Drug Profile 178
Product Description 178
Mechanism of Action 178
R&D Progress 178
Lytixar - Drug Profile 199
Product Description 199
Mechanism of Action 199
R&D Progress 199
Synflorix + Hiberix - Drug Profile 201
Product Description 201
Mechanism of Action 201
R&D Progress 201
Heptavalent Pneumococcal Conjugate Vaccine + Polyvalent Pneumococcal Vaccine - Drug Profile 202
Product Description 202
Mechanism of Action 202
R&D Progress 202
Rifabutin + Trimethoprim - Sulfamethoxazole - Drug Profile 204
Product Description 204
Mechanism of Action 204
R&D Progress 204
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 206
Product Description 206
Mechanism of Action 206
R&D Progress 206
Recombinant Human Beta-Defensin-2 - Drug Profile 208
Product Description 208
Mechanism of Action 208
R&D Progress 208
GSK-2189242-A - Drug Profile 209
Product Description 209
Mechanism of Action 209
R&D Progress 209
Staphylococcus Aureus Vaccine - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
cadazolid - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 239
SEB-HuMab - Drug Profile 270
Product Description 270
Mechanism of Action 270
R&D Progress 270
PlyD-1 - Drug Profile 271
Product Description 271
Mechanism of Action 271
R&D Progress 271
Quadrivan - Drug Profile 294
Product Description 294
Mechanism of Action 294
R&D Progress 294
PTX-002 - Drug Profile 295
Product Description 295
Mechanism of Action 295
R&D Progress 295
PTX-005 - Drug Profile 296
Product Description 296
Mechanism of Action 296
R&D Progress 296
PTX-006 - Drug Profile 297
Product Description 297
Mechanism of Action 297
R&D Progress 297
MCB-3837 - Drug Profile 304
Product Description 304
Mechanism of Action 304
R&D Progress 304
Gram-Positive Bacterial Infections Therapeutics – Drug Profile Updates 305
Gram-Positive Bacterial Infections Therapeutics – Discontinued Products 327
Gram-Positive Bacterial Infections Therapeutics - Dormant Products 328
Gram-Positive Bacterial Infections – Product Development Milestones 332
Featured News & Press Releases 332
Oct 02, 2012: Optimer Pharma Introduces Strategic Initiative To Further Facilitate Patient Access To Dificid 332
Sep 27, 2012: AvidBiotics Receives SBIR Grant For Avidocin Antibacterial Proteins Against Clostridium Difficile 333
Sep 25, 2012: Summit Receives Regulatory Approval To Commence Phase I Clinical Trial Of Selective Antibiotic For Treatment Of C. Difficile Infections 333
Sep 17, 2012: GSK Announces Submission For New Indication For Synflorix In Europe 334
Sep 12, 2012: Trius Therapeutics Reports Preclinical Data On Broad-Spectrum Antibiotics At 52nd Annual ICAAC Meeting 334
Sep 11, 2012: PolyMedix Presents New Data On Defensin-Mimetic Antibiotics At 52nd Annual ICAAC 2012 335
Sep 11, 2012: Trius Therapeutics Announces Data Presentations On Tedizolid At 52nd Annual ICAAC Meeting 336
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 337
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 338
Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 339
Appendix 341
Methodology 341
Coverage 341
Secondary Research 341
Primary Research 341
Expert Panel Validation 341
Contact Us 342
Disclaimer 342

List of Tables
Number of Products Under Development for Gram-Positive Bacterial Infections, H2 2012 23
Products under Development for Gram-Positive Bacterial Infections – Comparative Analysis, H2 2012 24
Number of Products under Development by Companies, H2 2012 26
Number of Products under Development by Companies, H2 2012 (Contd..1) 27
Number of Products under Development by Companies, H2 2012 (Contd..2) 28
Number of Products under Development by Companies, H2 2012 (Contd..3) 29
Number of Products under Development by Companies, H2 2012 (Contd..4) 30
Number of Products under Development by Companies, H2 2012 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 33
Comparative Analysis by Late Stage Development, H2 2012 34
Comparative Analysis by Mid Clinical Stage Development, H2 2012 35
Comparative Analysis by Early Clinical Stage Development, H2 2012 36
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 37
Products under Development by Companies, H2 2012 38
Products under Development by Companies, H2 2012 (Contd..1) 39
Products under Development by Companies, H2 2012 (Contd..2) 40
Products under Development by Companies, H2 2012 (Contd..3) 41
Products under Development by Companies, H2 2012 (Contd..4) 42
Products under Development by Companies, H2 2012 (Contd..5) 43
Products under Development by Companies, H2 2012 (Contd..6) 44
Products under Development by Companies, H2 2012 (Contd..7) 45
Products under Development by Companies, H2 2012 (Contd..8) 46
Products under Investigation by Universities/Institutes, H2 2012 47
Sequella, Inc., H2 2012 48
AstraZeneca PLC, H2 2012 49
GlaxoSmithKline plc, H2 2012 50
Genentech, Inc., H2 2012 51
Merck & Co., Inc., H2 2012 52
Emergent BioSolutions Inc., H2 2012 53
ACE BioSciences A/S, H2 2012 54
Nanotherapeutics, Inc., H2 2012 55
Rib-X Pharmaceuticals, Inc., H2 2012 56
Nabi Biopharmaceuticals, H2 2012 57
Actelion Ltd, H2 2012 58
BioMarin Pharmaceutical Inc., H2 2012 59
Cubist Pharmaceuticals, Inc., H2 2012 60
Forest Laboratories, Inc., H2 2012 61
Pfizer Inc., H2 2012 62
ViroPharma Incorporated, H2 2012 63
Wockhardt Limited, H2 2012 64
Hadasit Medical Research Services & Development Ltd, H2 2012 65
Optimer Pharmaceuticals, Inc., H2 2012 66
Paratek Pharmaceuticals, Inc., H2 2012 67
XTL Biopharmaceuticals Ltd., H2 2012 68
Affinium Pharmaceuticals, Inc., H2 2012 69
Immtech Pharmaceuticals, Inc., H2 2012 70
Intercell AG, H2 2012 71
Basilea Pharmaceutica Ltd., H2 2012 72
Biota Holdings Limited, H2 2012 73
Nymox Pharmaceutical Corporation, H2 2012 74
Oragenics, Inc., H2 2012 75
Patrys Limited, H2 2012 76
CytoGenix, Inc., H2 2012 77
ADVENTRX Pharmaceuticals, H2 2012 78
SIGA Technologies, Inc., H2 2012 79
XOMA Ltd., H2 2012 80
Immuron Limited, H2 2012 81
Dongwha Pharm Co., Ltd., H2 2012 82
Theravance, Inc., H2 2012 83
Panacea Biotec Limited, H2 2012 84
Summit Corporation plc, H2 2012 85
Phynova Group Ltd, H2 2012 86
Eurocine Vaccines AB, H2 2012 87
PolyMedix, Inc., H2 2012 88
e-Therapeutics plc, H2 2012 89
Morphotek, Inc., H2 2012 90
ActogeniX NV, H2 2012 91
Bharat Biotech International Limited, H2 2012 92
Mucosis B.V., H2 2012 93
Evolva SA, H2 2012 94
Novacta Biosystems Limited, H2 2012 95
GlycoVaxyn AG, H2 2012 96
ConjuGon, Inc., H2 2012 97
PLANTON GmbH, H2 2012 98
ImmunoBiology Limited, H2 2012 99
Aquapharm Biodiscovery Limited, H2 2012 100
Osel Inc., H2 2012 101
AiCuris GmbH & Co. KG, H2 2012 102
Destiny Pharma Ltd., H2 2012 103
NovaDigm Therapeutics, Inc., H2 2012 104
Ferrer Internacional S.A., H2 2012 105
Kenta Biotech Ltd., H2 2012 106
aRigen Pharmaceuticals, Inc., H2 2012 107
Sinovac Biotech Ltd., H2 2012 108
Viral Genetics, Inc., H2 2012 109
Microbiotix, Inc., H2 2012 110
Integrated BioTherapeutics, Inc., H2 2012 111
KYORIN Pharmaceutical Co., Ltd., H2 2012 112
Trius Therapeutics, Inc., H2 2012 113
Genocea Biosciences, Inc., H2 2012 114
Biosynexus Incorporated, H2 2012 115
Lytix Biopharma AS, H2 2012 116
Phico Therapeutics Ltd., H2 2012 117
NasVax Ltd., H2 2012 118
Sorrento Therapeutics, Inc., H2 2012 119
PepTx, Inc., H2 2012 120
Morphochem AG, H2 2012 121
Cantab Biopharmaceuticals Limited, H2 2012 122
Assessment by Monotherapy Products, H2 2012 123
Assessment by Combination Products, H2 2012 124
Assessment by Stage and Route of Administration, H2 2012 126
Assessment by Stage and Molecule Type, H2 2012 129
Gram-Positive Bacterial Infections Therapeutics – Drug Profile Updates 305
Gram-Positive Bacterial Infections Therapeutics – Discontinued Products 327
Gram-Positive Bacterial Infections Therapeutics – Dormant Products 328
Gram-Positive Bacterial Infections Therapeutics – Dormant Products (Contd..1) 329
Gram-Positive Bacterial Infections Therapeutics – Dormant Products (Contd..2) 330
Gram-Positive Bacterial Infections Therapeutics – Dormant Products (Contd..3) 331

List of Figures
Number of Products under Development for Gram-Positive Bacterial Infections, H2 2012 23
Products under Development for Gram-Positive Bacterial Infections – Comparative Analysis, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 32
Late Stage Products, H2 2012 34
Mid Clinical Stage Products, H2 2012 35
Early Clinical Stage Products, H2 2012 36
Discovery and Pre-Clinical Stage Products, H2 2012 37
Assessment by Monotherapy Products, H2 2012 123
Assessment by Combination Products, H2 2012 124
Assessment by Route of Administration, H2 2012 125
Assessment by Stage and Route of Administration, H2 2012 126
Assessment by Molecule Type, H2 2012 127
Assessment by Stage and Molecule Type, H2 2012 128

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos